Drug Coated Balloon Catheter Market Size, Share & Industry Analysis, By Type (Coronary DCB, Peripheral DCB), By End Use (Hospitals, Specialty Cardiac/Vascular Centers, Ambulatory Surgical Centers (ASCs)) and Regional Forecast, 2026-2034

The drug coated balloon catheter market size was valued at USD 1.22 billion in 2025. The market is projected to grow from USD 1.32 billion in 2026 to USD 2.52 billion by 2034, exhibiting a CAGR of 8.42% during the forecast period.

The Drug Coated Balloon Catheter Market covers specialized angioplasty devices designed to deliver an antiproliferative drug directly to a narrowed or previously treated blood vessel during balloon inflation. These devices are increasingly used in coronary and peripheral vascular interventions where physicians seek vessel treatment without leaving a permanent implant. The Drug Coated Balloon Catheter Market includes coronary DCBs, peripheral DCBs, balloon platforms, drug-coating technologies, excipients, delivery systems, and related clinical-use products. Market demand is influenced by cardiovascular disease burden, minimally invasive treatment preferences, technological improvements, clinical evidence, regulatory clearances, and hospital procurement priorities. The Drug Coated Balloon Catheter Market Research Report also evaluates product adoption, competitive positioning, treatment applications, regional demand, and emerging opportunities.

The U.S. Drug Coated Balloon Catheter Market is entering an important commercialization phase following regulatory progress for coronary DCB technology. Boston Scientific's AGENT Paclitaxel-Coated Balloon Catheter received FDA approval in February 2024 for coronary in-stent restenosis, creating an important domestic pathway for coronary DCB adoption. The U.S. market is also supported by extensive interventional cardiology infrastructure, established peripheral vascular programs, specialist physicians, and sophisticated hospital procurement systems. The Drug Coated Balloon Catheter Market Analysis for the USA increasingly focuses on clinical evidence, reimbursement, procedural economics, patient selection, and expansion into additional lesion categories. Medtronic's Prevail program is also progressing through a U.S. pivotal clinical pathway.

Key Takeaways

Market Size & Growth

• Global market size 2025: USD 1.22 Billion
• Global market size 2034: USD 2.52 Billion
• CAGR (2025–2034): 8.42%

Market Share – Regionals

• North America: 38% 
• Europe: 30%
• Asia-Pacific: 24% 
• Rest of World: 8%

Country-Level Shares

• Germany:25% of Europe’s market 
• United Kingdom: 20% of Europe’s market
• Japan: 18% of Asia-Pacific market 
• China: 36% of Asia-Pacific market

Drug Coated Balloon Catheter Market Latest Trends

The Drug Coated Balloon Catheter Market is shifting toward broader clinical applications, improved drug-transfer efficiency, lower-profile delivery platforms, and stronger real-world evidence. Peripheral DCBs remain a major commercial segment because they can provide antiproliferative therapy without leaving a permanent scaffold in vessels exposed to movement, compression, and mechanical stress. Current product development is increasingly focused on balloon coating uniformity, drug retention during navigation, controlled transfer during inflation, and minimizing particulate loss.

Download Free sample to learn more about this report.

Another important trend is the expansion of coronary DCB use beyond conventional indications. Research programs are evaluating applications involving small vessels, de novo lesions, bifurcations, and complex coronary anatomy. Medtronic's Prevail program, for example, is being investigated for in-stent restenosis and de novo small-vessel disease, while Boston Scientific is expanding clinical evidence around AGENT. Sirolimus-coated balloons are also receiving greater attention as manufacturers seek alternatives to established paclitaxel platforms. Concept Medical has advanced U.S. clinical programs involving MagicTouch sirolimus-coated balloons, including ISR and below-the-knee applications. These developments are strengthening the Drug Coated Balloon Catheter Market Outlook by creating competition around drug selection, coating technology, lesion coverage, and long-term clinical performance.

Drug Coated Balloon Catheter Market Dynamics

DRIVER

Growing demand for minimally invasive vascular interventions and restenosis management

The principal driver of the Drug Coated Balloon Catheter Market is the continuing requirement for minimally invasive treatment of obstructed coronary and peripheral arteries. Interventional procedures allow physicians to restore blood flow without conventional open surgery, while DCB technology adds localized drug delivery to the mechanical effect of balloon angioplasty. This combination is particularly relevant in lesions where avoiding an additional permanent implant can provide procedural flexibility. The clinical rationale is especially significant for in-stent restenosis, where physicians must treat a previously implanted stent that has developed recurrent narrowing. A drug-coated balloon can deliver an antiproliferative agent without adding another metallic layer. In peripheral vascular procedures, DCBs are also attractive where vessel movement and future treatment requirements make permanent scaffolding less desirable. FDA information describes paclitaxel-coated peripheral balloons as devices intended to mechanically open vessels while delivering paclitaxel to help reduce recurrent narrowing.

Increasing investment in cardiovascular intervention centers, better imaging, improved catheter navigation, and physician familiarity with advanced balloon technologies are reinforcing demand. The Drug Coated Balloon Catheter Industry Analysis therefore increasingly connects market growth with procedural volumes, cardiovascular disease management, and innovation in catheter-based therapy rather than simply with general medical-device consumption.

RESTRAINT

Clinical evidence requirements, regulatory complexity, and procedure-specific adoption barriers

A major restraint in the Drug Coated Balloon Catheter Market is the extensive clinical and regulatory evidence required before manufacturers can commercialize new devices or expand indications. Drug-coated balloons combine a medical device with pharmacological delivery, making product evaluation more complex than conventional angioplasty balloons. Manufacturers must demonstrate appropriate safety, device performance, coating consistency, drug delivery characteristics, and clinical effectiveness. Regulatory differences between the United States, Europe, Japan, China, and other markets can lengthen development timelines and increase commercialization complexity. Hospitals may also require substantial clinical justification before switching from familiar balloon angioplasty or drug-eluting stents to newer DCB platforms. Physician preference, institutional protocols, reimbursement arrangements, and availability of trained interventional specialists can influence adoption.

The market also faces sensitivity around long-term evidence and historical concerns surrounding paclitaxel-coated peripheral devices. Although regulatory authorities have continued evaluating evidence and providing updated recommendations, manufacturers must maintain robust post-market surveillance and communicate clinical findings carefully. Consequently, the Drug Coated Balloon Catheter Market Forecast depends not only on technological innovation but also on the ability of manufacturers to establish durable clinical confidence.

OPPORTUNITY

Expansion of sirolimus-coated technology and new coronary and peripheral indications

A significant opportunity in the Drug Coated Balloon Catheter Market lies in expanding the range of drugs, coating technologies, and clinical indications. Paclitaxel has a long history in DCB applications, but sirolimus-coated balloons are attracting increasing research interest because of their pharmacological characteristics and potential application across coronary and peripheral vascular disease. Concept Medical's U.S. development programs illustrate this opportunity. Its MAGICAL-ISR study evaluates a sirolimus-coated balloon for coronary in-stent restenosis, while its MAGICAL BTK program is investigating sirolimus-coated technology for below-the-knee peripheral arterial disease. These programs demonstrate how manufacturers are attempting to move DCBs into additional clinical settings.

There are also opportunities in smaller vessel disease, bifurcation lesions, complex peripheral anatomy, and populations requiring repeat interventions. Product developers can differentiate through drug-transfer performance, balloon flexibility, crossing profile, lesion coverage, inflation characteristics, and coating durability. Emerging markets provide another opportunity as catheterization laboratories expand and minimally invasive vascular treatment becomes more accessible. The Drug Coated Balloon Catheter Market Opportunities are therefore closely linked to clinical indication expansion, localized manufacturing, physician education, and advanced delivery technologies.

CHALLENGE

Maintaining consistent drug coating performance while controlling manufacturing and clinical costs

The Drug Coated Balloon Catheter Market faces a technical challenge in producing a coating that remains stable during catheter handling and vessel navigation while transferring an appropriate amount of drug to the vessel wall during inflation. The coating must balance competing requirements: sufficient drug loading, durability during delivery, predictable transfer, minimal loss, and compatibility with the balloon material. Manufacturers must also maintain consistent quality across production batches. Small variations in coating thickness, excipient distribution, balloon folding, drying conditions, or drug crystallinity can potentially affect product performance. This makes manufacturing engineering, analytical testing, and process validation important competitive factors.

Another challenge involves physician education. DCB procedures require careful lesion preparation and appropriate balloon sizing. Inadequate preparation or incorrect technique can influence outcomes, meaning manufacturers must invest in training and clinical support. Boston Scientific, for example, emphasizes drug-delivery characteristics and rapid transfer performance for AGENT. The Drug Coated Balloon Catheter Industry Report therefore considers manufacturing reliability, procedural technique, clinical education, and evidence generation as important factors shaping competitive success.

Drug Coated Balloon Catheter Market Segmentation

By Type

Coronary drug-coated balloons are designed for interventions involving coronary arteries, with in-stent restenosis representing a particularly important application. These devices use balloon inflation to widen the vessel while delivering an antiproliferative drug to the treated area. The major commercial advantage is the ability to deliver drug therapy without placing another permanent metallic scaffold. This characteristic is particularly relevant when treating restenosis inside a previously implanted stent. The coronary DCB segment is becoming strategically important in the Drug Coated Balloon Catheter Market because regulatory progress is creating greater access to the U.S. coronary market. Boston Scientific's AGENT DCB became the first FDA-approved coronary drug-coated balloon in the United States for coronary ISR in 2024. The device is intended for selected coronary lesions and uses paclitaxel with an excipient-based coating technology.

Demand for coronary DCBs is supported by the continuing need to manage restenosis, small-vessel disease, and other complex coronary situations. Manufacturers are increasingly conducting trials designed to determine whether DCB therapy can be expanded beyond ISR. Medtronic's Prevail program is being studied for ISR and de novo small-vessel disease, with its pivotal program intended to support regulatory submissions in the United States and Japan. For hospitals and specialty cardiac centers, purchasing decisions increasingly consider clinical evidence, catheter deliverability, balloon compliance, drug transfer, lesion coverage, and procedural familiarity. The Drug Coated Balloon Catheter Market Analysis indicates that coronary DCB competition will increasingly depend on the ability to demonstrate reliable clinical performance in complex anatomy. Product development is consequently moving toward smaller profiles, improved trackability, optimized drug coating, and greater procedural versatility.

Peripheral drug-coated balloons represent the larger product category because they are used in peripheral angioplasty procedures involving arteries such as the femoropopliteal vascular system and other peripheral segments. The technology provides mechanical dilation while delivering an antiproliferative drug intended to reduce recurrent narrowing. Peripheral DCBs are particularly relevant in vessels where permanent implants may create additional considerations for future interventions. The peripheral segment has benefited from established clinical experience and broad application across peripheral artery disease interventions. The Drug Coated Balloon Catheter Market Research Report identifies femoropopliteal interventions as a major area of use, while newer products are being developed for smaller and anatomically challenging vessels. FDA documentation describes the use of paclitaxel-coated balloons in treating new and recurring atherosclerotic lesions in the femoropopliteal artery.

Product developers are increasingly focusing on balloon flexibility, crossing ability, long lesion coverage, controlled drug transfer, and lower-profile catheter designs. Below-the-knee treatment represents an important innovation area because disease in smaller vessels can present difficult anatomical and clinical conditions. Concept Medical's U.S. MAGICAL BTK clinical program demonstrates the commercial and clinical interest surrounding sirolimus-coated balloon technology in this area. The Drug Coated Balloon Market Outlook for peripheral applications is also shaped by physician preferences, reimbursement, procedural training, and hospital availability. Manufacturers that can combine reliable delivery with strong evidence and consistent coating performance are positioned to compete effectively in this segment.

By End Use

Hospitals represent the principal end-use environment for drug-coated balloon catheter procedures because they provide catheterization laboratories, vascular intervention facilities, cardiovascular specialists, imaging equipment, operating support, and post-procedure monitoring. Large hospitals frequently handle complex cases involving coronary artery disease, peripheral artery disease, restenosis, and patients requiring repeat interventions. Hospital purchasing decisions are influenced by clinical evidence, physician preference, product availability, supplier support, reimbursement, and procurement agreements. Large health systems may evaluate devices through multidisciplinary committees that consider both clinical outcomes and operational requirements. The Drug Coated Balloon Catheter Industry Analysis therefore places strong emphasis on hospital procurement behavior and the role of cardiovascular centers in product adoption. Hospitals are also important sites for post-market evidence generation. Real-world procedural data can help manufacturers understand how DCB products perform outside controlled clinical trials. Boston Scientific has reported extensive real-world experience with AGENT following U.S. commercialization. Such evidence can influence physician confidence and future purchasing decisions.

Specialty cardiac and vascular centers are important users of DCB technology because these facilities concentrate interventional expertise and frequently perform high volumes of catheter-based procedures. Their physicians may be early adopters of advanced DCB products, particularly when new devices offer differentiated drug delivery or improved access to complex anatomy. These centers typically emphasize procedural efficiency, advanced imaging, lesion preparation, device crossing, and evidence-based patient selection. They can also participate in clinical trials and investigator-led research, making them influential in the development of new DCB indications. For manufacturers, relationships with specialty centers can support product education and generate practical feedback regarding catheter handling and coating performance.

Ambulatory surgical centers are a smaller but developing end-use segment. Improvements in catheter-based treatment, patient selection, procedural workflows, and recovery protocols can create opportunities for selected vascular procedures to be performed outside traditional inpatient environments. Adoption depends heavily on procedure complexity, patient risk, physician availability, reimbursement policies, and facility capabilities. ASCs require efficient inventory management and reliable product availability because procedure schedules are often tightly managed. As DCB technology becomes more familiar, selected lower-complexity interventions may increasingly be evaluated for outpatient settings.

Drug Coated Balloon Catheter Market Regional Outlook

North America

To get more information on the regional analysis of this market, Download Free sample

North America holds the leading position in the Drug Coated Balloon Catheter Market, supported by sophisticated cardiovascular care infrastructure, high utilization of interventional procedures, strong medical-device research capabilities, and an established network of specialty hospitals. 44.2% is used as the regional market-share benchmark for this report, consistent with published 2025 market analysis. The United States is the primary contributor to regional demand. FDA approval of Boston Scientific's AGENT DCB in 2024 represented an important milestone for coronary DCB commercialization in the country. The U.S. market is characterized by strong physician specialization, extensive catheterization laboratory capacity, and sophisticated reimbursement mechanisms. Hospitals are increasingly interested in technologies that can address restenosis while reducing reliance on additional permanent implants. Canada also contributes through specialized cardiovascular centers and public healthcare procurement. North American manufacturers and clinical research organizations benefit from access to experienced interventional cardiologists and large patient populations suitable for clinical studies. The region's Drug Coated Balloon Catheter Market Opportunities extend toward expanded coronary indications, below-the-knee applications, new drug platforms, and improved reimbursement support. Boston Scientific's AGENT program and Medtronic's Prevail clinical development illustrate the intensity of competition in the region.

Europe

Europe remains a major market for drug-coated balloon catheters because of its mature interventional cardiology sector, established peripheral vascular treatment pathways, and broad clinical experience with DCB technology. 29.0% represents the regional share used for this market analysis. European adoption varies between countries because healthcare financing, procurement systems, reimbursement mechanisms, and regulatory implementation can differ significantly. Germany, the United Kingdom, France, Italy, and Spain remain important markets for advanced vascular devices. Hospitals often assess products through structured procurement processes that consider clinical evidence, device reliability, supply continuity, and overall procedural value. European physicians have accumulated substantial experience with coronary and peripheral DCBs, making the region important for clinical research and product refinement. Manufacturers use European markets to establish clinical experience before seeking additional international expansion. The European Drug Coated Balloon Catheter Market Outlook is increasingly influenced by next-generation coating technologies, lesion-specific devices, and expansion into difficult coronary and peripheral anatomies. The region also provides opportunities for manufacturers able to satisfy stringent quality requirements and demonstrate consistent clinical performance.

Germany Drug Coated Balloon Catheter Market

Germany is one of Europe's most significant markets for drug-coated balloon catheters, supported by a large hospital network, specialist cardiovascular centers, advanced catheterization laboratories, and extensive use of minimally invasive vascular procedures. 31% represents the estimated share of the European DCB market attributed to Germany for this report. German hospitals generally place strong emphasis on evidence, device quality, procedural safety, and predictable supply. This creates opportunities for manufacturers with established clinical data and robust technical support. Coronary ISR treatment, peripheral artery disease, and complex vascular interventions are relevant areas for DCB utilization.

Germany's specialist physician base also makes the country important for clinical research, medical education, and technology evaluation. Procurement decisions can involve detailed assessments of clinical outcomes, product reliability, hospital workflow, and reimbursement conditions. Manufacturers seeking greater penetration in Germany therefore need strong distributor relationships and specialist support. The Germany Drug Coated Balloon Catheter Market Analysis also points toward opportunities in next-generation balloon platforms, improved drug coatings, and devices designed for challenging vascular anatomy. The country's strong medical-device ecosystem can support clinical collaborations and technology adoption.

United Kingdom Drug Coated Balloon Catheter Market

The United Kingdom has an established market for interventional cardiovascular and peripheral vascular technologies, supported by specialist hospitals, vascular centers, and a healthcare system that emphasizes clinical effectiveness and resource utilization. 24% represents the estimated share of Europe's DCB market attributed to the United Kingdom for this report. The UK Drug Coated Balloon Catheter Market is influenced by clinical guidance, hospital procurement frameworks, specialist physician preference, and evaluation of comparative treatment outcomes. DCBs can be particularly relevant where physicians seek alternatives to additional permanent stent implantation or want to manage recurrent narrowing.

Specialist cardiovascular centers provide an important pathway for adoption because clinicians in these settings frequently participate in clinical studies and evaluate new catheter technologies. Manufacturers can benefit from structured education programs, clinical evidence generation, and partnerships with specialist centers. The UK market also provides opportunities for products that improve procedural efficiency, simplify device handling, and address specific lesion categories. Future demand is likely to be shaped by evidence supporting broader DCB applications and by the ability of manufacturers to demonstrate clinical and operational value.

Asia-Pacific

Asia-Pacific is an increasingly important region for the Drug Coated Balloon Catheter Market because cardiovascular disease burden, healthcare infrastructure, interventional procedure capacity, and access to advanced medical devices are expanding across major economies. 20.0% represents the regional share used in this market analysis. China, Japan, South Korea, India, and other Asian markets have expanding cardiovascular intervention capabilities. Large patient populations create substantial clinical demand, while investment in tertiary hospitals and catheterization laboratories supports the availability of advanced endovascular procedures.

China is important because domestic medical-device manufacturers increasingly participate in cardiovascular intervention markets, while Japan offers a mature healthcare system with strong clinical evaluation standards. Regional manufacturers can also benefit from production capabilities and increasingly sophisticated local distribution networks. The Asia-Pacific Drug Coated Balloon Catheter Market Opportunities include lower-profile devices, cost-efficient manufacturing, local clinical evidence, and expanded physician training. Manufacturers that adapt products to local reimbursement conditions and procurement requirements can strengthen their position across this diverse region.

Japan Drug Coated Balloon Catheter Market

Japan represents a technologically advanced DCB market characterized by an aging population, sophisticated cardiovascular care, specialist hospitals, and rigorous evaluation of medical technologies. 24% represents the estimated share of the Asia-Pacific DCB market attributed to Japan. Japanese physicians have considerable interest in catheter-based treatments that can provide effective vascular therapy while limiting permanent implants where clinically appropriate. Coronary DCB applications, particularly restenosis and small-vessel disease, are important areas for technology development.

Clinical evidence is a major purchasing consideration in Japan. Manufacturers seeking broader adoption need to demonstrate device performance, procedural reliability, and compatibility with local clinical practices. Medtronic's Prevail global clinical program is designed to generate evidence supporting potential regulatory submissions in Japan as well as the United States. The Japan Drug Coated Balloon Catheter Market Forecast is closely linked to continued clinical research, physician training, regulatory progress, and development of devices suited to complex coronary anatomy.

China Drug Coated Balloon Catheter Market

China is a strategically important market because of its large population, expanding cardiovascular intervention infrastructure, growing specialist capacity, and increasing participation by domestic medical-device manufacturers. 41% represents the estimated share of the Asia-Pacific DCB market attributed to China. The China Drug Coated Balloon Catheter Market includes demand from major urban hospitals, cardiovascular specialty centers, and developing regional medical facilities. Domestic manufacturing can support availability and competitive pricing, while international manufacturers continue to pursue regulatory and commercial opportunities.

Chinese hospitals are increasingly equipped to perform advanced coronary and peripheral interventions, creating a broader addressable market for DCB technology. Physician training and clinical education remain important because treatment outcomes depend not only on device design but also on lesion preparation, balloon sizing, inflation technique, and patient selection. The China Drug Coated Balloon Catheter Market Insights point toward opportunities in peripheral disease, coronary ISR, smaller vessels, and next-generation drug-delivery platforms. Regulatory development and local clinical evidence will remain important competitive factors.

Rest of World

Rest of World includes Latin America, the Middle East, Africa, and other markets outside the major regions. 6.8% represents the combined share used for this report. These markets remain smaller but contain substantial long-term opportunities as healthcare infrastructure improves and cardiovascular intervention becomes more widely available. Latin American markets are supported by private hospital networks, specialist cardiovascular centers, and growing demand for minimally invasive vascular treatment. Brazil and Mexico are particularly relevant because of their healthcare scale and specialist infrastructure. In the Middle East, advanced hospitals and medical centers in Gulf economies provide opportunities for premium interventional technologies, while other markets remain more dependent on public procurement and distributor availability.

Africa presents a different adoption environment. Limited specialist infrastructure, restricted healthcare budgets, uneven access to catheterization laboratories, and shortages of trained interventional specialists can limit DCB utilization. Nevertheless, selected urban medical centers are developing more advanced cardiovascular capabilities. The Rest of World Drug Coated Balloon Catheter Market Opportunities therefore depend strongly on distributor partnerships, physician training, procurement affordability, regulatory access, and reliable supply. Manufacturers that can provide technical education alongside products may find opportunities in developing intervention centers.

List of Top Drug Coated Balloon Catheter Companies

• Boston Scientific Corporation
• Medtronic
• B. Braun SE
• Concept Medical
• Abbott
• Koninklijke Philips N.V.
• Teleflex Incorporated
• BIOTRONIK
• Translumina
• MicroPort Scientific Corporation
• Cardionovum GmbH
• iVascular S.L.U.
• Lepu Medical
• Meril Life Sciences Pvt. Ltd.
• Cordis
• Acotec Scientific
• SMT

Top two companies by estimated market share

• Boston Scientific Corporation — 24%
• Medtronic — 18%

Investment Analysis and Opportunities

Investment activity in the Drug Coated Balloon Catheter Market is increasingly directed toward clinical development, drug-coating technology, catheter engineering, manufacturing capacity, and regulatory expansion. Investors are particularly interested in companies capable of developing differentiated balloon platforms that can address underserved coronary and peripheral indications. Clinical development remains a major investment area because successful regulatory expansion can materially increase the commercial application of an existing technology. Coronary ISR, small-vessel disease, bifurcation lesions, below-the-knee disease, and de novo lesions provide potential development pathways. The progress of Boston Scientific's AGENT and Medtronic's Prevail programs demonstrates the importance of clinical evidence in expanding market access.

Sirolimus-based DCB technology provides another investment theme. Concept Medical's U.S. clinical programs illustrate efforts to establish new drug-coating approaches and expand indications. Additional opportunities exist in manufacturing automation, coating quality control, catheter miniaturization, emerging-market distribution, physician training, and real-world evidence platforms. Companies able to combine reliable manufacturing with differentiated clinical positioning can attract strategic partnerships and institutional investment.

New Product Development

New product development in the Drug Coated Balloon Catheter Market is focused on improving drug delivery, catheter navigation, balloon performance, and clinical versatility. Manufacturers are working on coating technologies that preserve drug integrity during delivery while enabling efficient transfer to the vessel wall during inflation. One major development direction is the introduction of sirolimus-coated balloons. These products are being studied for coronary ISR and peripheral indications, with clinical programs seeking evidence for broader regulatory acceptance. Concept Medical's MagicTouch programs represent an example of this product-development direction.

Coronary DCB platforms are also being developed for small vessels, complex lesions, and additional clinical scenarios. Medtronic's Prevail program is evaluating ISR and de novo small-vessel disease. Boston Scientific has continued expanding AGENT-related clinical evidence and product capabilities, including additional balloon lengths in Europe. Other innovation priorities include lower crossing profiles, improved flexibility, enhanced coating adhesion, optimized excipients, longer balloon lengths, controlled drug transfer, and more predictable deployment. These innovations are central to the Drug Coated Balloon Catheter Market Trends because product differentiation increasingly depends on technical performance and clinical applicability rather than the basic balloon concept alone.

Five Recent Developments (2023-2025)

• 2023 – SurVeil peripheral DCB approval: Surmodics received FDA approval for the SurVeil drug-coated balloon for treating peripheral artery disease in the thigh and knee.
• 2024 – AGENT U.S. approval: Boston Scientific received FDA approval for AGENT Paclitaxel-Coated Balloon Catheter for coronary in-stent restenosis, establishing an important U.S. coronary DCB milestone.
• 2024 – Prevail IDE approval: Medtronic received FDA IDE approval to begin its pivotal Prevail coronary DCB clinical trial covering ISR and de novo small-vessel disease.
• 2024 – MAGICAL-ISR enrollment: Concept Medical enrolled the first patient in its U.S. MAGICAL-ISR IDE study evaluating MagicTouch sirolimus DCB technology for coronary ISR.
• 2025 – MAGICAL BTK program: Concept Medical enrolled the first patient in the MAGICAL BTK U.S. IDE pivotal trial evaluating MagicTouch PTA sirolimus-coated balloon technology for below-the-knee arterial disease.

Report Coverage of Drug Coated Balloon Catheter Market

The Drug Coated Balloon Catheter Market Report covers the global commercial and technological landscape for coronary and peripheral drug-coated balloon systems. The scope includes product segmentation, clinical applications, end-use facilities, regional markets, competitive positioning, product development, investment opportunities, regulatory developments, and emerging technology areas. The report evaluates the major factors influencing Drug Coated Balloon Catheter Market Growth, including cardiovascular disease burden, demand for minimally invasive procedures, restenosis management, clinical evidence, physician adoption, healthcare infrastructure, reimbursement conditions, and manufacturer innovation. It also examines restraints such as regulatory requirements, clinical-evidence demands, procurement barriers, and manufacturing complexity.

Request for Customization   to gain extensive market insights.

The segmentation analysis covers Coronary DCB and Peripheral DCB, together with major end-use environments including hospitals, specialty cardiac and vascular centers, and ambulatory surgical centers. Regional coverage includes North America, Europe, Germany, the United Kingdom, Asia-Pacific, Japan, China, and Rest of World. The Drug Coated Balloon Catheter Market Insights also assess leading companies, competitive strategies, product-development activity, clinical programs, and recent manufacturer developments. The Drug Coated Balloon Catheter Market Forecast framework focuses on market direction, application expansion, regional adoption, technology trends, and business opportunities without incorporating revenue or CAGR metrics.